{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:29:46Z","timestamp":1787156986368,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["A-0006187-00-00"],"award-info":[{"award-number":["A-0006187-00-00"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2024\/064\/NUSMed\/05\/SynCTI2.0"],"award-info":[{"award-number":["NUHSRO\/2024\/064\/NUSMed\/05\/SynCTI2.0"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["A-8001920-00-00"],"award-info":[{"award-number":["A-8001920-00-00"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["T2EP30123-0045"],"award-info":[{"award-number":["T2EP30123-0045"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-MSG-2023-0003"],"award-info":[{"award-number":["NRF-MSG-2023-0003"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.copbio.2026.103521","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:32:21Z","timestamp":1780306341000},"page":"103521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Engineering red cells across scales: Red Blood Cells (RBCs) and RBC-derived extracellular vesicles"],"prefix":"10.1016","volume":"100","author":[{"given":"Ziyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9421-9390","authenticated-orcid":false,"given":"Gloria Mei En","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2026.103521_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-9-5","article-title":"Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial","volume":"9","author":"Chessa","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.copbio.2026.103521_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1474-4422(24)00220-5","article-title":"Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"23","author":"Zielen","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.copbio.2026.103521_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.18152","article-title":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","volume":"197","author":"Lynggaard","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.copbio.2026.103521_bib4","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.18373","article-title":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","volume":"198","author":"Albertsen","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.copbio.2026.103521_bib5","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO-25-00872","article-title":"TRYBECA-1: a randomized phase III study of eryaspase combined with chemotherapy versus chemotherapy as second-line treatment in patients with advanced pancreatic adenocarcinoma","volume":"43","author":"Hammel","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.copbio.2026.103521_bib6","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00262-021-03001-7","article-title":"Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15","volume":"70","author":"McArdel","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.copbio.2026.103521_sbref7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s43018-026-01125-2","article-title":"Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1\/PDL1: preclinical characterization and results of a phase 1 trial","volume":"7","author":"Nie","year":"2026","journal-title":"Nat Cancer"},{"issue":"Pt A","key":"10.1016\/j.copbio.2026.103521_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","article-title":"Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems","volume":"106","author":"Villa","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2026.103521_bib9","first-page":"95","article-title":"Drug delivery by red blood cells","volume":"8","author":"Biagiotti","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.copbio.2026.103521_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3389\/fphys.2019.01070","article-title":"Red blood cell membrane processing for biomedical applications","volume":"10","author":"Rossi","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.copbio.2026.103521_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121202","article-title":"Clinical progress and advanced research of red blood cells based drug delivery system","volume":"279","author":"Li","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.copbio.2026.103521_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.905256","article-title":"Recent progress in red blood cells-derived particles as novel bioinspired drug delivery systems: challenges and strategies for clinical translation","volume":"10","author":"Vincy","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.copbio.2026.103521_bib13","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1021\/acsnano.2c11965","article-title":"Advances in drug delivery systems based on red blood cells and their membrane-derived nanoparticles","volume":"17","author":"Nguyen","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.copbio.2026.103521_bib14","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.3390\/biomedicines11102798","article-title":"Red blood cell-derived extracellular vesicles: an overview of current research progress, challenges, and opportunities","volume":"11","author":"Ma","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.copbio.2026.103521_bib15","unstructured":"Rubius Therapeutics, Inc: Annual report (Form 10-K) for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission; 2023."},{"key":"10.1016\/j.copbio.2026.103521_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13287-023-03367-8","article-title":"Immortalized erythroid cells as a novel frontier for in vitro blood production: current approaches and potential clinical application","volume":"14","author":"Cervellera","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.copbio.2026.103521_bib17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/cells12111554","article-title":"Generation of red blood cells from human pluripotent stem cells-an update","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.copbio.2026.103521_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOH.0000000000000810","article-title":"Generation of red blood cells from induced pluripotent stem cells","volume":"31","author":"Gunawardena","year":"2024","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.copbio.2026.103521_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1308632","article-title":"Drug transport by red blood cells","volume":"14","author":"Biagiotti","year":"2023","journal-title":"Front Physiol"},{"key":"10.1016\/j.copbio.2026.103521_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7150\/thno.87425","article-title":"Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications","volume":"14","author":"Zhang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.copbio.2026.103521_bib21","first-page":"890","article-title":"Establish tolerance in MS with myelin-peptide coupled red blood cells - the phase Ib ETIMSred trial","volume":"25","author":"Lutterotti","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.copbio.2026.103521_sbref21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114681","article-title":"Engineering red blood cells for antigen-specific immune tolerance and personalized therapy of autoimmune diseases","volume":"392","author":"Yuan","year":"2026","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2026.103521_sbref22","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41467-026-71013-x","article-title":"In vivo metabolic tagging and targeting of circulating red blood cells","volume":"17","author":"Liu","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.copbio.2026.103521_sbref23","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1073\/pnas.1409861111","article-title":"Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes","volume":"111","author":"Shi","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2026.103521_bib25","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.1701746114","article-title":"Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease","volume":"114","author":"Pishesha","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2026.103521_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-017-00448-0","article-title":"Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin","volume":"8","author":"Huang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.copbio.2026.103521_sbref26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady6730","article-title":"In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy","volume":"18","author":"Nie","year":"2026","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2026.103521_sbref27","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA drug delivery using red blood cell extracellular vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.copbio.2026.103521_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.761362","article-title":"Red blood cell extracellular vesicle-based drug delivery: challenges and opportunities","volume":"8","author":"Chiangjong","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.copbio.2026.103521_sbref29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65623-y","article-title":"Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules","volume":"14","author":"Biagiotti","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.copbio.2026.103521_bib31","article-title":"Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect","volume":"60","author":"Chiangjong","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.copbio.2026.103521_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106665","article-title":"Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery","volume":"188","author":"Pham","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.copbio.2026.103521_bib33","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.7150\/thno.68667","article-title":"Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy","volume":"12","author":"Jayasinghe","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.copbio.2026.103521_sbref33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011148","article-title":"Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia","volume":"13","author":"Liu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.copbio.2026.103521_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13622","article-title":"Dendritic cell-targeted delivery of antigens using extracellular vesicles for anti-cancer immunotherapy","volume":"57","author":"Dang","year":"2024","journal-title":"Cell Prolif"},{"key":"10.1016\/j.copbio.2026.103521_sbref35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1039\/D5BM01349F","article-title":"Red blood cell-derived extracellular vesicles as biomaterials: the opportunity of freezing-induced accelerated aging","volume":"14","author":"Paolini","year":"2026","journal-title":"Biomater Sci"},{"key":"10.1016\/j.copbio.2026.103521_bib37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/s41598-022-04915-7","article-title":"Storage conditions determine the characteristics of red blood cell extracellular vesicles","volume":"12","author":"Bebesi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.copbio.2026.103521_sbref37","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103891","article-title":"Impact of production methods and storage conditions on extracellular vesicles in packed red blood cells and platelet concentrates","volume":"63","author":"Ebeyer-Masotta","year":"2024","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.copbio.2026.103521_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000342524","article-title":"A double in vivo biotinylation technique for objective assessment of aging and clearance of mouse erythrocytes in blood circulation","volume":"39","author":"Saxena","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.copbio.2026.103521_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10928-016-9470-4","article-title":"Models for the red blood cell lifespan","volume":"43","author":"Shrestha","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.copbio.2026.103521_bib41","first-page":"196","article-title":"Determination of RBC survival in C57BL\/6 and C57BL\/6-Tg(UBC-GFP) mice","volume":"65","author":"Dholakia","year":"2015","journal-title":"Comp Med"},{"key":"10.1016\/j.copbio.2026.103521_sbref41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214234","article-title":"Erythrocyte membrane vesicles as drug delivery systems: a systematic review of preclinical studies on biodistribution and pharmacokinetics","volume":"170","author":"Kostevsek","year":"2025","journal-title":"Biomater Adv"},{"key":"10.1016\/j.copbio.2026.103521_bib43","unstructured":"U.S. Food and Drug Administration: Potency assurance for cellular and gene therapy products: draft guidance for industry. Center for Biologics Evaluation and Research; December 2023."},{"key":"10.1016\/j.copbio.2026.103521_bib44","unstructured":"U.S. Food and Drug Administration: Manufacturing changes and comparability for human cellular and gene therapy products: draft guidance for industry. Center for Biologics Evaluation and Research; July 2023."},{"key":"10.1016\/j.copbio.2026.103521_bib45","unstructured":"European Medicines Agency: Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. EMA\/CAT\/22473\/2025; 2025. Effective 1 July 2025."},{"key":"10.1016\/j.copbio.2026.103521_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.copbio.2026.103521_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202400242","article-title":"Engineering of erythrocytes as drug carriers for therapeutic applications","volume":"9","author":"Jia","year":"2025","journal-title":"Adv Biol"},{"key":"10.1016\/j.copbio.2026.103521_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJN.S579975","article-title":"Red blood cell-derived extracellular vesicles for gene and RNA therapeutics: biological, engineering, and translational challenges","volume":"21","author":"Shafiq","year":"2026","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.copbio.2026.103521_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13739","article-title":"IL-12 minicircle delivery via extracellular vesicles as immunotherapy for bladder cancer","volume":"58","author":"Wu","year":"2025","journal-title":"Cell Prolif"},{"key":"10.1016\/j.copbio.2026.103521_sbref46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114239","article-title":"Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment","volume":"387","author":"Nguyen","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2026.103521_bib51","article-title":"Extracellular vesicles administered via intrathecal injection mediate safe delivery of nucleic acids to the central nervous system for gene therapy","volume":"14","author":"Lam","year":"2025","journal-title":"J Extra Vesicles"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166926000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166926000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:00:37Z","timestamp":1787155237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166926000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S0958166926000868"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2026.103521","relation":{},"ISSN":["0958-1669"],"issn-type":[{"value":"0958-1669","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering red cells across scales: Red Blood Cells (RBCs) and RBC-derived extracellular vesicles","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2026.103521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103521"}}